DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Viridian Announces Positive Data From Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients With Thyroid Eye Disease (TED)
Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced positive topline clinical data from the first two cohorts in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the body’s own immune system attacks the tissues around and behind the eyes causing inflammation, swelling, and damage that develops into debilitating signs and symptoms including double vision, bulging eyes, and ocular pain.
“These additional Phase 1/2 clinical data continue to support the potential for VRDN-001 to be a new treatment option for patients suffering from TED,” said Raymond Douglas, M.D., Ph.D., director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center and an investigator on the VRDN-001 trial.


Related Content
-
Evidence & EducationRacial Disparities in Thyroid Surgery: Summary for the PublicBackground: Recent protests over police...
-
Evidence & EducationGraves’ Disease After Treatment With Alemtuzumab for Multiple SclerosisContext: Alemtuzumab, a humanized monoc...
-
People & PlacesBritish Thyroid AssociationThe British Thyroid Association (BTA) is...
-
Videos & VisualsUnderstanding Autoimmune Thyroid Diseasehttps://www.youtube.com/watch?v=Gl1-INPQ...
-
Evidence & Education2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thy...Background: Thyrotoxicosis has multip...
-
People & PlacesBeth Israel Deaconess Medical Center – Thyroid CenterThe Thyroid Center, the Division of Endo...
-
Evidence & EducationAssociation of Radioactive Iodine Treatment With Cancer Mortality in Patients With HyperthyroidismImportance Radioactive iodine (RAI) h...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.